Company Overview
Snapshot
Founded in October 2012 by Boaz Harari and Prof. Menahem Neuman, FEMSelect operates with 11–50 employees. The company has raised $16.89M across 7 funding rounds from 14 investors. In October 2022, FEMSelect secured Series B financing with New Age Ventures as a lead investor.
Business overview
FEMSelect is a Health Tech & Life Sciences company focused on developing innovative solutions for women's health. Its core product, EnPlace, is a minimally invasive and mesh-free system designed for pelvic floor ligament fixation. The EnPlace procedure, which takes approximately 30 minutes, utilizes a patented delivery system for precise anchor deployment through the vaginal wall, securing it to the pelvic floor ligament for stabilization. The device, which is FDA cleared and CE marked, combines a Nitinol-based anchor, surgical sutures, and an attachment method, eliminating the need for deep dissection or mesh. FEMSelect serves the medical devices market, targeting doctors, surgeons, and hospitals with treatments for pelvic organ prolapse.
Strategic signal
In June 2023, FEMSelect was highlighted for its innovative pelvic floor solutions, signaling a continued focus on improving women's quality of life through advanced medical technology. This indicates the company's ongoing commitment to market penetration and the strategic validation of its EnPlace system within the healthcare industry.
Log in to access full profile ›Company Intelligence Q&A
- What is FEMSelect's primary product?
- FEMSelect's primary product is EnPlace, a minimally invasive and mesh-free system designed for pelvic floor ligament fixation, offering a novel approach to treating pelvic organ prolapse.
- When did FEMSelect receive FDA clearance for its pelvic device?
- FEMSelect's pelvic device, EnPlace, was given FDA clearance in August 2016.
- Which investors participated in FEMSelect's Series B financing round?
- In October 2022, FEMSelect raised Series B financing with participation from investors including New Age Ventures.
- Has FEMSelect received any government grants?
- Yes, in January 2012, FEMSelect secured a grant from the Israel Innovation Authority.
- When did FEMSelect announce CMS reimbursement for its pelvic organ prolapse repair procedure?
- FEMSelect announced CMS reimbursement for its innovative minimally invasive approach to pelvic organ prolapse repair procedure in November 2021.